BRD2 and cancer: In particular, we observed a remarkable decrease in the number of cells within post-NAT tumors in cancer clusters 2, 4, 5, 9, and 10, whereas clusters 1 and 11 may potentially represent cell subsets demonstrating an adaptive immune resistance to NAT.